Pharmacokinetics of oral lidocaine and nifedipine in patients with liver cirrhosis

Journal of the Medical Association of Thailand

Volumn 79, Issue 5, 1996, Pages

  Tonsuwannont, Wittaya ^a   Praisontarangkul, Ong Ard ^b   Manorot, Majleeya ^a   Klangwarnwong, Darawan ^c  

^a Departments of Pharmacology

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c Lanna Hospital   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

LIDOCAINE; NIFEDIPINE;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; FEMALE; HEART RATE; HUMAN; LIVER CIRRHOSIS; MALE; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANESTHETICS; CROSS-OVER STUDIES; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; LIDOCAINE; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NIFEDIPINE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; VASODILATOR AGENTS;

EID: 3042970290     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearances. Clin Pharmacol Ther 1975; 18: 377-90.
2. Huet PM, Villeneuve JP. Determinants of drug disposition in patients with cirrhosis. Hepatology 1983; 6: 913-8.
3. Branch RA. Drugs as indicators of hepatic function. Hepatology 1982; 2: 97-105.
4. Gianelly R, von der Groeben JO, Spivack AP, et al. Effect of lidocaine on ventricular arrhythmias in patients with coronary heart disease. N Engl J Med 1967; 277: 1215-9.
5. Thomson PD, Melmon KL, Richardson JA, et al. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med 1973; 78: 489-508.
6. Guazzi M, Olivari MT, Polese A, et al. Nifedipine, a new antihypertensive with rapid action. Clin Pharmacol Ther 1977; 22: 528-32.
7. Kleinbloesem CH, Van Brummelen P, Van de Linde JA, et al. Nifedipine : Kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 1984; 35: 742-9.
8. Pietta P, Rawa A, Biondi P. High-performance liquid chromatography of nifedipine, its metabolites and photochemical products. J Chromatography 1981; 210: 516-21.
9. Bennett PN, Aarons LJ, Bending MR, et al. Pharmacokinetics of lidocaine and its deethylated metabolite: Dose and Time dependency studies in man. J Pharmacokin Biopharm 1982; 10: 265-81.
10. Forrest JAH, Finlayson NDC, Adjepon-Yamoah KK, et al. Antipyrine, Paracetamol, and lignocaine elimination in chronic liver disease. Br Med J 1977; 1: 1384-7.
11. Foster TS, Hamann SR, Richards VR, et al. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J Clin Pharmacol 1983; 23: 161-70.
12. Renwick AG, Le Vie J, Challenor VF, et al. Factors affecting the pharmacokinetics of nifedipine. Eur J Clin Pharmacol 1987; 32: 351-5.
13. Kleinbloesem CH, Van Brummelen P, Faber H, et al. Variability in nifedipine pharmacokinetics and dynamics : a new oxidation polymorphism in man. Biochem Pharmacol 1984; 33: 3721-4.
14. Nakashima T, Inoki M, Nakanishi Y. Nifedipine serum concentration; effects upon blood pressure and heart rate in normotensive volunteers. Eur J Drug Met Pharmacokinet 1984; 9: 73-8 .
15. Higuchi S, Shiobara Y. Quantitative determination of nifedipine in human plasma by selected ion monitoring. Biomed Mass Spec 1978; 5: 220-3.
16. Ene MD, Roberts CJC. Pharmacokinetics of nifedipine after oral administration in chronic liver disease. J Clin Pharmacol 1987; 27: 1001-4.
17. Williams RL, Mamelok RD. Hepatic disease and drug pharmacokinetics. Clin Pharmacokinet 1980; 5: 528-47.
18. Gutierrez LM, Lesklo LJ, Whipps R, et al. Pharmacokinetics and pharmacodynamics of nifedipine in patients at steady state. J Clin Pharmacol 1986; 26: 587-92.
19. Waller DG, Renwick AG, Gruchy BS, et al. The first pass metabolism of nifedipine in man. Br J Clin Pharmacol 1984; 18: 951-4.
20. Raemsch KD, Sommer J. Pharmacokinetics and metabolism of nifedipine. Hypertension 1983; 5: II-18-II-24.
21. Hoyo-Vadillo C, Castaneda-Hernandez G, Herrera JE, et al. Pharmacokinetics of oral nifedipine relevance of distribution phase. J Clin Pharmacol 1989; 29: 251-6.
22. Kleinbloesem CH, Van Harten J, Wilson JPH, et al. Nifedipine : Kinetics and hemodynamic effect in patients with liver cirrhosis after intravenous and oral administration. Clin Pharmacol Ther 1986; 40: 21-8.
23. Aoki K, Sato K, Kawaguchi Y, et al. Acute and long-term hypotensive effects and plasma concentrations of nifedipine in patients with essential hypotension. Eur J Clin Pharmacol 1982; 23: 197-201.
24. Murakami M, Murakami E, Takekoshi N, et al, Antihypertensive effect of 4 (-2′-nitrophenyl) -2, 6-dimethyl-1, 4-dihydropyridine-3, 5-dicarbonic acid dimethylester (nifedipine, Bay-a 1040), a new coronary dilator. Jap Heart J 1972; 13: 128-35.
25. Kuroda T, Yokoyama T, Umeda T, et al. Pharmacokinetics of nifedipine and prediction of plasma concentration on essential hypertensive patients. Kobe J Med Sci 1985; 31: 133-44.